How to Outsource Biosimilar Development and Comparability Without Losing Control

The development of biosimilars represents a significant opportunity within the pharmaceutical industry, particularly in the biologics sector. However, navigating the regulatory landscape, including comparability assessments and compliance with relevant guidelines, requires a thorough understanding of regulatory expectations from agencies such as the FDA, EMA, and MHRA. This article serves as a comprehensive manual for Regulatory Affairs (RA) professionals in the realm of biosimilar development and comparability biologics regulation.

Context

Biosimilars are biologic products that are highly similar to an FDA-approved reference product, with no clinically meaningful differences in terms of safety, purity, and potency. The drafting of biosimilar development plans often necessitates the involvement of external partners, such as contract research organizations (CROs) or other specialized companies that enhance technical capability and increase resource availability. This raises unique challenges, particularly regarding oversight, compliance assurance, and maintaining control over regulatory submissions. This article will provide critical insights into how RA teams can effectively manage outsourcing while meeting regulatory obligations.

Legal/Regulatory Basis

In the United States, biosimilars are regulated under the Biologics Control Act and subsequently by the Biologics Price Competition and Innovation Act (BPCIA). The FDA outlines requirements for demonstrating biosimilarity in guidance documents, which detail the necessary comparative analyses and clinical studies required for approval. In the EU, Regulation (EC) No 726/2004 and the corresponding Guideline on Similar Biological Medicinal Products established a comprehensive legal framework that governs the authorization of biosimilars. Similarly, in the UK, the regulatory framework follows the principles set forth by the EMA but is governed under MHRA guidelines post-Brexit.

Documentation

Outsourcing involves careful documentation to ensure compliance with regulatory expectations and proper communication between parties. Key documentation elements include:

• Development Plan: A detailed outline of the biosimilar development strategy, including timelines, milestones, and responsibilities.
• Quality Agreements: Clearly defined roles regarding quality control, testing, and regulatory submission responsibilities between the sponsor and the CROs.
• Study Protocols: Comprehensive protocols governing the conduct of preclinical and clinical studies essential for demonstrating biosimilarity.
• Data Management Plans: Protocols for data collection, management, and reporting to ensure integrity and compliance.

Review/Approval Flow

Understanding the regulatory review process is critical, particularly when outsourcing. The general path for FDA, EMA, and MHRA reviews includes the following stages:

1. Pre-Submission Activities: Engage in early discussions with regulatory agencies to clarify expectations. Submit a pre-BLA (Biologics License Application) meeting request for the FDA or equivalent in the EU.
2. Submission of Application:
   • Prepare and submit the BLA or application including all relevant data comparing the biosimilar to the reference product.
   • A comprehensive comparison that includes analytical, preclinical, and clinical data is essential.
3. Regulatory Review: After submission, the assigned regulatory body will review the application for quality, safety, and efficacy. This often includes collaborative assessments with the outsourcing partner.
4. Post-Approval Monitoring:
   • Once approved, continuous post-market surveillance becomes essential to ensure ongoing compliance with established safety profiles.

Common Deficiencies

When managing the outsourcing of biosimilar development, awareness of common deficiencies that lead to delays or rejections can mitigate regulatory risks. Typical issues include:

• Insufficient Comparability Data: Failing to provide robust analytical data demonstrating similarity can result in requests for additional information or outright rejection.
• Inadequate Quality Assurance: Any lapses in quality management systems employed by CROs can lead to severe regulatory ramifications.
• Documentation Gaps: Missing or poorly organized documentation can hinder seamless communication with regulatory agencies, leading to prolonged review times.

RA-Specific Decision Points

When planning the regulatory strategy for outsourcing, critical decision points must be considered:

When to File as a Variation vs. New Application

The determination of whether to approach a biosimilar as a new application or a variation can significantly impact the review process. The general rule is as follows:

• Variation: If the biosimilar is closely aligned with the original product and does not introduce significant changes in the design or intended use, it might be filed as a variation.
• New Application: Divergences in formulation, indication, or major shifts in manufacturing processes may necessitate a new application submission rather than a variation.

Justifying Bridging Data

A common challenge in outsourcing arises when bridging data requirements between the reference product and the biosimilar. Clear justifications must be provided when bridging studies are conducted with data generated at a different site:

• Scientific Rationale: A robust scientific justification explaining the necessity of bridging studies and their relevance to the intended comparability assessment.
• Methodological Consistency: Ensure that the methodologies used in bridging studies align closely with those employed in previous studies of the reference product.
• Regulatory Engagement: Early consultation with the relevant regulatory authority can provide clarity on what bridging data will be acceptable based on the established scientific context.

Working with External Partners

Establishing strong partnerships with CROs or other outsourcing entities is critical in mitigating regulatory risks associated with biosimilar development:

Choosing the Right Partner

Selecting a CRO with proven regulatory experience in biosimilars can add significant value. Essential considerations include:

• Experience and Track Record: Evaluate past performance and approvals related to biosimilars or other complex biologics.
• Regulatory Knowledge: The partner should demonstrate an in-depth understanding of FDA, EMA, and MHRA guidelines and expectations.
• Quality Management Systems: The CRO should possess robust quality systems with a successful track record in managing compliance-related issues.

Maintaining Control over Development

Maintaining control during outsourcing is paramount. This can be accomplished through:

• Regular Communication: Establish frequent, structured updates between internal teams and external partners to ensure alignment on objectives and project milestones.
• Defined KPIs: Develop key performance indicators that ensure transparency and accountability during various stages of product development.
• Continuous Monitoring: Implementing oversight mechanisms to monitor operational activities, data integrity, and compliance with regulated activities is vital.

Conclusion

Biosimilar development and comparability present unique regulatory challenges, especially when outsourcing components of the process. By understanding the regulatory landscape, documenting effectively, and maintaining strong partnerships with external entities, RA professionals can navigate the complexities of biosimilar development while minimizing the risks of non-compliance. Emphasizing communication, rigorous documentation, and adherence to agency expectations will ultimately lead to more efficient regulatory pathways and approval processes, contributing to the successful introduction of safe and effective biosimilars into the market.

For more information on biosimilar regulations and guidelines, you may refer to the FDA Guidance on Biosimilars, or check the EMA’s Guidelines for Biosimilars.